Depot fluspirilene for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Abhijnhan, Akhil ^a   Adams, C E ^b   David, A ^b   Ozbilen, M ^b  

^a Academic Unit of Psychiatry and Behavioural Sciences   (United Kingdom)

^b NONE

Author keywords

Administration, oral; Antipsychotic agents administration dosage; *therapeutic use ; Delayed action preparations administration dosage; therapeutic use ; Fluspirilene administration dosage; * therapeutic use

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; FLUSPIRILENE; LORAZEPAM; NEUROLEPTIC AGENT; OXAZEPAM; PERPHENAZINE ENANTHATE; PIPOTIAZINE UNDECENOATE; PLACEBO; TRIFLUOPERAZINE; ZOTEPINE;

ANTICHOLINERGIC EFFECT; AUTONOMIC NEUROPATHY; DIZZINESS; DROWSINESS; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; INJECTION SITE PAIN; MENTAL HEALTH; MOTOR DYSFUNCTION; OCULOGYRIC CRISIS; PERSISTENT VEGETATIVE STATE; RELAPSE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 44949131851     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001718.pub2     Document Type: Review

References (65)

1. Angst 1973 {published data only} Angst J, Frei M, Scharfetter C. The depot neuroleptic agent fluspirilene [Das Depotneurolepticum Fluspirilen. Klinische Pruefung im offenen Versuch und als Doppelblindstudie im Vergleich zu Fluphenazin Decanoat]. Pharmakopsychiatrie und Neuropsychopharmakologie 1973;6(1):13-28. [MEDLINE: 74281360].
2. Bankier 1973 {published data only} Bankier RG. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis. Journal of Clinical Pharmacology and The Journal of New Drugs 1973;13(1):44-7. [MEDLINE: 4566123].
3. Borger 1978 {published data only} Borger J, Van Epen JH, Dekkers A. A double-blind clinical evaluation of different dose intervals with fluspirilene (IMAP). Acta Psychiatria Belgica 1978;78:383-91.
4. Chouinard 1986 {published data only} Chouinard G, Annable L, Steinberg S. A controlled clinical trial of flusipirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. Journal of Clinical Psychopharmacology 1986;6(1):21-6.
5. Frangos 1978 {published data only} Frangos H, Zississ NP, Leontopoulos I, Diamentas N, Tsitouridis S, Gavriil I, Tsolis K. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatrica Scandinavica 1978;57:436-46.
6. Galfi 1973 {published data only} Galfi B, Benson K, Grynaeus T. Results with the sustained-action neuroleptic fluspirilene on chronic schizophrenic patients undergoing occupational therapy [Erfahrungen mit dem anhaltend wirkenden Neuroleptikum Fluspirilene bei arbeitstherapeutisch beschaftigten chronisch Schizophrenen]. International Pharmacopsychiatry 1973;8(1):37-59. [MEDLINE: 74138149].
7. Magnus 1979 {published data only} Magnus RV. A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy 1979;2(3):109-14.
8. Magnus RV. Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin-Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift 1980;122:1758-60. [MEDLINE: 72195113].
9. Malm 1974 {published data only} Malm U, Perris C, Rapp W, Wedren G. A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes. Acta Psychiatrica Scandinavica Supplementum 1974;249:94-116.
10. Russell 1982 {published data only} Russell N, Landmark J, Merskey H, Turpin T. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry 1982;27:593-6.
11. Tegeler 1979 {published data only} Tegeler J, Floru L. A comparative study of the long acting neuroleptics perphenazin enanthate and fluspirilene [Eine Vergleichende Untersuchung Der Depot-Neuroleptika Perphenazin Onanthat Und Fluspirilen]. Pharmakopsychiatrie und Neuropsychopharmakologie 1979;12(5):357-65.
12. Vereecken 1972 {published data only} Veerecken JLTH, Tanghe A. Fluspirilene and pipothiazine undecylenate, two long-acting injectable neuroleptics. Psychiatria, Neurologia, Neurochirurgia 1972;75:117-27.
13. Villeneuve 1970 {published data only} Villeneuve A, Dogan K, Lachance R, Proulx C. A controlled study of fluspirilene in chronic schizophrenia. Current Therapeutic Research, Clinical and Experimental 1970;12(12):819-27. [MEDLINE: 4994687].
14. Angst 1975 Angst J, Woggon B. Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, fluspirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate [Klinische Prufung von funf Depotneuroleptika. Vergleich der Wirkungsprofile von Fluphenazindecanoat, Fluspirilen, Penfluridol, Perphenazinoenanthat und Pipothiazinpalmitat]. Arzneimittel Forschung 1975;25(2):267-70. [MEDLINE: 75127650].
15. Chouinard 1983 Chouinard G, Annable L. Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacology Bulletin 1983;19(1):136-8.
16. Demerdash 1981 Demerdash A, Mazhar N, El-Hanbali M, Abou-Ghazala E. A double-blind trial of fluspirilene versus flupenthixol decanoate in the treatment of schizophrenic inpatients. Journal of The Kuwait Medical Association 1981;15:7-16.
17. Den Boer 2000 Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89.
18. Faltus 1974 Faltus F. The depot compounds moditen (fluphenazine) and IMAP (flusipirilene) in clinical practice. Activitas Nervosa Superior 1974;16(3):167-8.
19. Faltus 1976 Faltus F, Soucek K. Treatment of Schizophrenia using depot neuroleptics. Ceskoslovenska Psychiatrie 1976;3:170-75.
20. Gravem 1981 Gravem A, Elgen K. Cis(Z) clopenthixol. The neuroleptically active isomer of clopenthixol. A presentation of five double blind clinical investigations and other studies with cis(Z) clopenthixol (Cisordinol(R), Clopixol(R)). Acta Psychiatrica Scandinavica Supplementum 1981;64(294):5-12. [MEDLINE: 6122337].
21. Huygens 1973 Huygens H, Vereecken JL, Tanghe A. Dexetimide (R 16470) in the control of neuroleptic induced extrapyramidal side effects - its prophylactic value and duration of action. Psychiatria Neurologia Neurochirurgia 1973;76(4):251-9.
22. Immich 1970 Immich H, Eckmann F, Neumann H, Schapperle O, Schwarz H, Tempel H. Joint clinical study of a long term neuroleptic drug fluspirilene [Klinische Gemeinschaftsuntersuchung mit dem Langzeit-Neurolepticum Fluspirilene]. Arzneimittelforschung 1970;20:1699-1701.
23. Linden 1973 Linden KJ, Knaack M, Edel W. Combination of rating scales and handwriting test for objective evaluation and quantifying neuroleptic effects. A double blind study with fluspirilene and penfluridol [Die Kombination von Rating Scales und Handschrifttest zur Objektivierung und Quantifizierung neuroleptischer Effekte. Eine Doppelblindstudie mit Fluspirilene und Penfluridol]. Psychopharmacology, sexual disorders and drug abuse : proceedings of the Symposia held at VIII Congress of the Colleguim Internationale Neuro-Psychopharmacologicum ; 1972 Aug 14-17, Copenhagen. Amsterdam, Netherlands: 1973:273-8.
24. Moller 2004 *Moller HJ, Riedel M, Muller N, Fischer W, Kohnen R. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004;37(6):270-8. [MEDLINE: 15551193].
25. Schmider 1999 Schmider J, Standhart H, Deuschle M, Drancoli J, Heuser I. A double blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biological Psychiatry 1999;46(3):437-41. [MEDLINE: 99364070].
26. Skopova 1985 Skopova J, Faltus F, Filip V, Jirak R, Karen P, Posmurova M, Dobiasova A. Fluspirilene in schizophrenia maintenance therapy and its interaction with dexetimide [Fluspirilen v udrzovaci lecbe schizofrenie a jeho interakce s dexetimidem]. Ceskoslovenska Psychiatrie 1985;81(6):414-9. [MEDLINE: 3912068].
27. Tanghe 1972 *Tanghe A, Vereecken JL. Fluspirilene, an injectable, and penfluridol, an oral long-acting, neuroleptic. A comparative double-blind trial in residual schizophrenia. Acta Psychiatrica Scandinavica 1972;48(4):315-31. [MEDLINE: 4566564].
28. Vereecken 1971 Vereecken JLTM. Comparative study of two depot neuroleptics: pipothiazine, 19551 RP, and fluspirilene [Etude comparitive de deux neuroleptiques retard: la pipothiazine, 19551 RP, et le fluspirilène]. 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Mexico City, Mexico. 1971:566.
29. Vranckx-Haenen 1979 Vranckx-Haenen J, De Munter W, Heykants J. Fluspirilene (IMAP) administered in a biweekly dose for the prevention of relapses in chronic schizophrenics. Acta Psychiatrica Belgica 1979;79:45-74.
30. Winter 1973 Winter K, Fullerton AG, Hussain K, Tarlo L. A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia. British Journal of Clinical Practice 1973;27(10):377-80.
31. Pluymakers 1971
32. Aaes-Jorgenson 1985 Aaes-Jorgenson A. Pharmacokinetics of oral and depot neuroleptics - clinical relevance. Symposium Espo. Feb 1, 1985.
33. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
34. Ban 1978 Ban TA. The AMDP system. Proc. Xth Congress of C.I.N.P. Pergamon Press, London.(English version). London: Pergamon Press, 1978:1575-1579.
35. Barnes 1994 Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. Drug Safety 1994;10(6):464-79.
36. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
37. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
38. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
39. Chouinard 1971 Chouinard G, Ban TA, Lehmann HE. Fluspirilene in the treatment of chronic schizophrenic patients. Current Therapeutic Research 1971;12:604-8.
40. Chouinard 1980 Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science 1980;7:233.
41. Curson 1985 Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic outpatients: the seven-year follow-up of the medical research council fluphenazine/placebo trial. British Journal of Psychiatry 1985;146:464-80.
42. David 1994 David AS, Cutting JC. The neuropsychology of schizophrenia. Hove, E. Sussex: Lawrence Erlbaum Associates, 1994.
43. Davis 1977 Davis JM, Casper R. Antipsycotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14:260-82.
44. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
45. Dencker 1980 Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica 1980;61(Suppl 279):64-76.
46. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
47. DoH 1996 Department of Health, NHS Executive. Burdens of disease: a discussion document. London: HMSO, 1996.
48. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
49. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
50. Guy 1976 Guy U. ECDEU Assessment manual for psychopharmacology. DHEW publication No (ADM). ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:124-585.
51. Haynes 1979 Haynes RB, Taylor WD, Sackett DL. Compliance in health care. Baltimore: Johns Hopkins University Press, 1979.
52. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
53. Higgins 2005 Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: Higgins JPT, GreenS editor (s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2005.
54. Hirsch 1973 Hirsch SR, Gaind R, Rohde PD. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. British Medical Journal 1973;1:633-7.
55. Jablensky 1992 Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen ASO. Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study. Psychological Medicine (Monograph Supplement) 1992;20:1-97.
56. Kane 1998 Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998;8:55-66.
57. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
58. McGee 1983 McGee HM, Seeman MV, Deck JH. Fluspirilene neuroleptic depot and indurations. Canadian Journal of Psychiatry 1983;28:379-81.
59. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
60. Schmidt 1989 Schmidt LG. Utilization and safety of fluspirilene in non-psychotic outpatients. Pharmacopsychiatry 1989;22:188-91.
61. Schulz 1994 Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125-8.
62. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
63. Simon 1995 Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology 1995;48:363-73.
64. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75. [MEDLINE: 10982317].
65. David 1999 David A, Adams CE, Quraishi SN. Depot fluspirilene for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 3.Art. No.: CD001718. DOI:10.1002/14651858.CD001718.pub2.